scholarly journals Malignant Müllerian Mixed Tumor of the Uterine Cervix with a Small Cell Neuroendocrine Carcinoma Component

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Satoru Munakata ◽  
Emi Iwai ◽  
Tomohito Tanaka ◽  
Michihiko Nakamura ◽  
Takayoshi Kanda
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Uterine Cervix ◽  
Pap Smear ◽  
English Literature ◽  
Pelvic Lymphadenectomy ◽  
Small Cell ◽  
Arterial Infusion ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Cervical Mass ◽  
Mixed Tumors

Malignant Müllerian mixed tumors (MMMTs) of the uterine cervix are extremely rare, accounting for 0.005% of all cervical malignancies. To date, only approximately 50 well-documented cases have been reported. Although several epithelial components have been described in cervical MMMTs, small cell neuroendocrine carcinoma (SCC) has not appeared in the English literature. We present a 43-year-old woman, para 2 gravida 2, who had MMMT with SCC and rhabdomyosarcoma components in the uterine cervix. She was referred to our hospital because of a cervical mass with an abnormal Pap smear result. Cervical biopsy revealed SCC. After neoadjuvant chemotherapy with balloon-occluded arterial infusion, she underwent type II radical hysterectomy with pelvic lymphadenectomy. Histological analysis revealed that the cervical tumor comprised SCC and rhabdomyosarcoma components. Genotype analysis indicated human papillomavirus type 18. She underwent concurrent chemoradiation therapy. The patient had been free of the disease and showed no evidence of recurrence 38 months after operation.

Small cell neuroendocrine carcinoma of uterine cervix: The Scottish experience

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15026-15026
Author(s):  
M. Siva ◽  
R. Mahmood ◽  
S. Kakumanu ◽  
A. Sadozye ◽  
N. Reed
Keyword(s):  
Overall Survival ◽  
Neuroendocrine Carcinoma ◽  
Uterine Cervix ◽  
Salvage Therapy ◽  
Total Abdominal Hysterectomy ◽  
Pelvic Lymphadenectomy ◽  
Small Cell ◽  
Therapeutic Interventions ◽  
Small Cell Neuroendocrine Carcinoma

15026 Background: Small cell neuroendocrine carcinoma (SCC) of uterine cervix is a rare sub-type of cervical cancer. We report the results of a retrospective analysis of data from 2 Scottish centres of cases of SCC of cervix. The aim is to examine therapeutic interventions, relapse patterns and survival. Methods: Eligible cases were patients (pts) with cervical SCC presented for management discussion between 1995 and 2005 in the 2 scottish centres. Pathology was reviewed centrally by the network pathologists. We reviewed pts case records for staging information, therapeutic interventions, median time to relapse, salvage therapy and responses and overall survival. Results: A total of 21 pts were eligible for the analysis (Glasgow-13 and Aberdeen-8). The median age of the pts was 33 (Range 22–74). Nine pts were FIGO stage 1B, 3 were 2A and 4 were 2B, 3 were 3B and 2 with metastatic disease. Surgery was done in 13 pts [11-radical hysterectomy/pelvic lymphadenectomy, 1-radical hyseterctomy and 1-total abdominal hysterectomy]. Chemotherapy was given to 16 pts [Neo-adjuvant-6, Adjuvant-9, Concurrent-3]. Fourteen pts received combination chemotherapy containing Platinum and Etoposide [EP-2, CE-8, ICE-1 and ACE-3]. One received non-platinum combination. Fourteen pts received radiotherapy [10-Pelvic radiotherapy and brachytherapy, 3-Pelvic only, 1-Brachytherapy only, 2-PCI]. Two pts died of progressive disease shortly after diagnosis without any specific anti-cancer treatment, two pts were disease free after a follow up of 40 and 53 months respectively and one was lost to follow up 7 yrs after diagnosis. Median relapse free survival (RFS) was 16 months. Two year RFS was 25%. The sites of relapse were as follows: Liver-4, Chest-4, Para-aortic-4, Brain-3, Neck-3, Local-2, Abdomen-1. Twelve pts received salvage therapy after relapse [5-responded, 2-not assessed and 5-progressed]. Seven pts were alive after a median follow up of 40 months [Range 17–90]. Median survival was 28 months and the three year overall survival was 45%. Conclusions: We have shown here that with combination treatment SCC can be effectively managed with occasional durable remissions. The overall survival at 3 years was 45%. We believe this was the result of aggressive combination therapy of surgery, chemo and radiotherapy. No significant financial relationships to disclose.

Primary Small Cell Neuroendocrine Carcinoma of the Vagina: A Clinicopathologic Study

2004 ◽  
Vol 128 (8) ◽  
pp. 857-862 ◽  
Author(s):  
Zhanyong Bing ◽  
Lyuba Levine ◽  
Joseph A. Lucci ◽  
Sandra S. Hatch ◽  
Mahmoud A. Eltorky
Keyword(s):  
Transcription Factor ◽  
Neuroendocrine Carcinoma ◽  
English Literature ◽  
Small Cell ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Therapeutic Modalities ◽  
Thyroid Transcription Factor 1 ◽  
Clinicopathologic Study ◽  
Thyroid Transcription Factor ◽  
Transcription Factor 1

Abstract Context.—Primary small cell neuroendocrine carcinoma of the vagina is extremely rare, and its clinical behavior is aggressive. To our knowledge, 22 patients with this tumor have been reported in the English literature to date. Objective.—To investigate 3 patients with this tumor clinically and pathologically. Design.—The pathology database at the University of Texas Medical Branch at Galveston was searched, and 3 cases of primary small cell neuroendocrine carcinoma of the vagina were found. The histologic, immunohistochemical, and ultrastructural profiles of the tumors were investigated. The medical charts of the patients were reviewed, and the patients were followed up. Patients.—Women with the diagnosis of primary small cell neuroendocrine carcinoma of vagina. Results.—All 3 patients presented with advanced disease, and 2 patients died within 4 months of the initial diagnosis. One 38-year-old patient was newly diagnosed, and her clinical outcome had not yet been determined. The histologic features of all 3 tumors were similar to those of their pulmonary counterpart. All cases were positive for cytokeratin, chromogranin A, and synaptophysin. The expression pattern of thyroid transcription factor 1 was examined in all 3 patients, of whom 2 were negative and 1 was positive with negative clinical and radiologic thyroid or pulmonary findings. Ultrastructural evaluation showed scattered intracytoplasmic electron-dense neurosecretory granules. Conclusion.—Primary small cell neuroendocrine carcinoma of the vagina has histologic, immunohistochemical, and ultrastructural features similar to those of its pulmonary counterpart. Because thyroid transcription factor 1 can be positive, it should not be used to differentiate primary from metastatic disease. The current therapies have usually resulted in poor outcomes, and new therapeutic modalities should be explored.

Expression of p21Cip1/Waf1 and p27Kip1 in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix

2008 ◽  
Vol 16 (1) ◽  
pp. 11-15 ◽  
Author(s):  
Tatsuki R. Kataoka ◽  
Yoshitane Tsukamoto ◽  
Makiko Matsumura ◽  
Asako Miyake ◽  
Shoji Kamiura ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Uterine Cervix ◽  
Small Cell ◽  
Small Cell Neuroendocrine Carcinoma
Sign in / Sign up

Export Citation Format

Share Document